Risk factors
Revelation Biosciences (REVB) risk factors
Item 1A of every Revelation Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks5 new2 dropped5 reworded
FDA staffing reductions and policy changes now threaten clinical trial timelines and product approvals. Nasdaq's proposed $5 million public float rule introduces delisting risks. The company narrowed its focus to GEM-AKI and GEM-CKD, dropping GEM-PSI.
Filed Feb 26, 2026 - FY2024 10-K risk factors66 risks
Revelation Biosciences relies entirely on early-stage preclinical candidates GEM-AKI, GEM-CKD, and GEM-PSI with no approved products or sales.
Filed Mar 06, 2025